Medivo Rebrands as Prognos to Leverage AI for Earlier Disease Detection

Thought you might find this interesting



Medivo Rebrands as Prognos to Leverage AI for Earlier Disease Detection

After six years of research and development exploring the potential of clinical diagnostic assets, Medivo has rebranded as Prognos. The new artificial intelligence-focused company mission is to help payer, life sciences and diagnostics organization track and predict disease earlier through advanced analytics and artificial intelligence techniques. The company is supported by a $23M investment from Safeguard Scientifics, Inc. and Merck Global Health Innovation Fund (GHIF).

Prognos has already partnered with Cigna, Biogen and Quest Diagnostics by offering access to its Prognos Registry, the largest source of clinical diagnostics information in over 30 disease areas, with over 5B medical records for 100M patients. Prognos has 500 extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. Cigna is already using Prognos analytics to improve health engagement among its Individual and Family Plan customers.

“Prognos’ analytics help us identify customers with chronic conditions such as diabetes, rheumatoid arthritis, and hepatitis C, so that we can engage them early and support them with health management options,” said Brian Evanko, president of Cigna’s Individual and Family Plans segment. “This helps drive better health outcomes for our customers, resulting in improved health care quality and a better customer experience.”

Key benefits of that AI platform include:

·       For Life Sciences, Prognos solutions help brands dependent on biomarkers educate providers on therapy options for newly-diagnosed patients – before treatment decisions are made. Unlike Rx or claims data, clinical diagnostics data comes before treatment decisions have been made; lab tests influence 70% of medical decisions and 100% of treatment decisions for some conditions.

·       For payers, Prognos solutions enable engagement with providers earlier in the patient treatment process to improve quality of care. This also reduces avoidable care costs, especially for patients with chronic conditions and comorbidities. Clinical diagnostic analytics can improve quality, HEDIS outcomes and Star ratings.

·       For patients, Prognos AI solutions mean better treatment decision-making and outcomes.

“The launch of Prognos elevates our ability to leverage the largest aggregated database of lab results in the U.S. and deliver actionable clinical insights to the medical community,” said Sundeep Bhan, Prognos Co-Founder and CEO in a statement.